An update of treatment options for neovascular age-related macular degeneration

Hong Kong Medical Journal

Volumn 13, Issue 6, 2007, Pages 460-470

  Iu, Lawrence P L ^a   Kwok, Alvin K H ^a  

^a HONG KONG SANATORIUM AND HOSPITAL   (Hong Kong)

Author keywords

Angiogenesis inhibitors; Choroidal neovascularization; Macular degeneration; Receptors, vascular endothelial growth factor; Treatment outcome

Indexed keywords

ALPHA TOCOPHEROL; ALPHA2A INTERFERON; ANECORTAVE; ANGIOGENESIS INHIBITOR; ANTIGLAUCOMA AGENT; ANTIOXIDANT; ASCORBIC ACID; BETA CAROTENE; BEVACIZUMAB; COPPER; CORTICOSTEROID; MATRIX METALLOPROTEINASE INHIBITOR; PEGAPTANIB; PLACEBO; PROTEIN KINASE C INHIBITOR; RANIBIZUMAB; SQUALAMINE; TRIAMCINOLONE; VASCULOTROPIN INHIBITOR; VERTEPORFIN; ZINC; VASCULOTROPIN A;

ABSENCE OF SIDE EFFECTS; ACUTE DISEASE; ANGIOGENESIS; BACKACHE; BLEEDING; BLOOD PRESSURE; CATARACT; CENTRAL RETINA ARTERY OCCLUSION; CEREBROVASCULAR ACCIDENT; CLINICAL PRACTICE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONJUNCTIVAL HEMORRHAGE; CONTROLLED CLINICAL TRIAL; CORNEA INJURY; DIGESTIVE SYSTEM PERFORATION; DISEASE COURSE; DISEASE SEVERITY; DRUG BINDING; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG RELEASE; ELDERLY CARE; ENDOPHTHALMITIS; EYE INFLAMMATION; EYE INJURY; EYE PAIN; EYE SURGERY; EYE TOXICITY; HUMAN; HYPERTENSION; INJECTION SITE DISCOMFORT; INTERMETHOD COMPARISON; INTRAOCULAR PRESSURE; KERATITIS; LASER COAGULATION; LENS INJURY; LOW DRUG DOSE; MONOTHERAPY; NONHUMAN; OUTCOME ASSESSMENT; PATHOGENESIS; PHOTODYNAMIC THERAPY; PHOTOSENSITIVITY; POSTOPERATIVE COMPLICATION; PROTEINURIA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RETINA DETACHMENT; RETINA DISEASE; RETINA HEMORRHAGE; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA TRANSLOCATION; RETINA NEOVASCULARIZATION; RETINA TEAR; REVIEW; SIDE EFFECT; SKIN COLOR; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; TRANSPUPILLARY THERMOTHERAPY; TRAUMATIC CATARACT; UNSPECIFIED SIDE EFFECT; UROGENITAL TRACT DISEASE; UVEITIS; VISUAL ACUITY; VISUAL AID; VISUAL DISORDER; VISUAL IMPAIRMENT; VITREOUS FLOATERS; WOUND HEALING IMPAIRMENT; DRUG ANTAGONISM; HYPERTHERMIC THERAPY; PHOTOCHEMOTHERAPY; RETINA MACULA DEGENERATION;

ADRENAL CORTEX HORMONES; ANGIOGENESIS INHIBITORS; HUMANS; HYPERTHERMIA, INDUCED; LASER COAGULATION; MACULAR DEGENERATION; PHOTOCHEMOTHERAPY; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 38849179545     PISSN: 10242708     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (98)

1. Seddon JM, Chen CA. The epidemiology of age-related macular degeneration. Int Ophthalmol Clin 2004;44:17-39.
2. Ferris FL 3rd, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 1984;102:1640-2.
3. Tezel TH, Bora NS, Kaplan HJ. Pathogenesis of age-related macular degeneration. Trends Mol Med 2004;10:417-20.
4. Chopdar A, Chakravarthy U, Verma D. Age related macular degeneration. BMJ 2003;326:485-8.
5. de Jong PT. Age-related macular degeneration. N Engl J Med 2006;355:1474-85.
6. Nowak JZ. Age-related macular degeneration (AMD): pathogenesis and therapy. Pharmacol Rep 2006;58:353-63.
7. Anderson DH, Mullins RF, Hageman GS, Johnson LV. A role for local inflammation in the formation of drusen in the aging eye. Am J Ophthalmol 2002;134:411-31.
8. Ng EW, Adamis AP. Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. Can J Ophthalmol 2005;40:352-68.
9. Amin R, Puklin JE, Frank RN. Growth factor localization in choroidal neovascular membranes of age-related macular degeneration. Invest Ophthalmol Vis Sci 1994;35:3178-88.
10. Argon laser photocoagulation for neovascular maculopathy. Three-year results from randomized clinical trials. Macular Photocoagulation Study Group. Arch Ophthalmol 1986;104:694-701.
11. Argon laser photocoagulation for neovascular maculopathy. Five-year results from randomized clinical trials. Macular Photocoagulation Study Group. Arch Ophthalmol 1991;109:1109-14. Erratum in: Arch Ophthalmol 1992;110:761.
12. Five-year follow-up of fellow eyes of patients with agerelated macular degeneration and unilateral extrafoveal choroidal neovascularization. Macular Photocoagulation Study Group. Arch Ophthalmol 1993;111:1189-99.
13. Recurrent choroidal neovascularization after argon laser photocoagulation for neovascular maculopathy. Macular Photocoagulation Study Group. Arch Ophthalmol 1986;104:503-12.
14. Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Macular Photocoagulation Study Group. Arch Ophthalmol 1991;109:1220-31.
15. Schmidt-Erfurth U, Laqua H, Schlotzer-Schrehard U, Viestenz A, Naumann GO. Histopathological changes following photodynamic therapy in human eyes. Arch Ophthalmol 2002;120:835-44.
16. Moshfeghi DM, Kaiser PK, Grossniklaus HE, et al. Clinicopathologic study after submacular removal of choroidal neovascular membranes treated with verteporfin ocular photodynamic therapy. Am J Ophthalmol 2003;135:343-50.
17. Scott LJ, Goa KL. Verteporfin. Drugs Aging 2000;16:139-48.
18. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials - TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Arch Ophthalmol 1999;117:1329-45.
19. Bressler NM; Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials - tap report 2. Arch Ophthalmol 2001;119:198-207.
20. Verteporfin In Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization - verteporfin in photodynamic therapy report 2. Am J Ophthalmol 2001;131:541-60.
21. Azab M, Benchaboune M, Blinder KJ, et al. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: meta-analysis of 2-year safety results in three randomized clinical trials: Treatment Of Age-Related Macular Degeneration With Photodynamic Therapy and Verteporfin In Photodynamic Therapy Study Report no. 4. Retina 2004;24:1-12.
22. Arnold JJ, Blinder KJ, Bressler NM, et al. Acute severe visual acuity decrease after photodynamic therapy with verteporfin: case reports from randomized clinical trials - TAP and VIP report no. 3. Am J Ophthalmol 2004;137:683-96.
23. Verteporfin Roundtable 2000 and 2001 Participants; Treatment of age-related macular degeneration with photodynamic therapy (TAP) study group principal investigators; Verteporfin in photodynamic therapy (VIP) study group principal investigators. Guidelines for using verteporfin (visudyne) in photodynamic therapy to treat choroidal neovascularization due to age-related macular degeneration and other causes. Retina 2002;22:6-18.
24. Verteporfin Roundtable Participants. Guidelines for using verteporfin (Visudyne) in photodynamic therapy for choroidal neovascularization due to age-related macular degeneration and other causes: update. Retina 2005;25:119-34.
25. Tatar O, Kaiserling E, Adam A, et al. Consequences of verteporfin photodynamic therapy on choroidal neovascular membranes. Arch Ophthalmol 2006;124:815-23.
26. Tatar O, Adam A, Shinoda K, et al. Expression of VEGF and PEDF in choroidal neovascular membranes following verteporfin photodynamic therapy. Am J Ophthalmol 2006;142:95-104.
27. Tatar O, Shinoda K, Adam A, et al. Effect of verteporfin photodynamic therapy on endostatin and angiogenesis in human choroidal neovascular membranes. Br J Ophthalmol 2007;91:166-73.
28. Rogers AH, Reichel E. Transpupillary thermotherapy of subfoveal occult choroidal neovascularization. Curr Opin Ophthalmol 2001;12:212-5.
29. Mainster MA, Reichel E. Transpupillary thermotherapy for age-related macular degeneration: long-pulse photocoagulation, apoptosis, and heat shock proteins. Ophthalmic Surg Lasers 2000;31:359-73.
30. Oosterhuis JA, Journee-de Korver HG, Kakebeeke-Kemme HM, Bleeker JC. Transpupillary thermotherapy in choroidal melanomas. Arch Ophthalmol 1995;113:315-21.
31. Reichel E, Berrocal AM, Ip M, et al. Transpupillary thermotherapy of occul t subfoveal choroidal neovascularization in patients with age-related macular degeneration. Ophthalmology 1999;106:1908-14.
32. Newsom RS, McAlister JC, Saeed M, McHugh JD. Transpupillary thermotherapy (TTT) for the treatment of choroidal neovascularisation. Br J Ophthalmol 2001;85:173-8. Erratum in: Br J Ophthalmol 2001;85:505.
33. Thach AB, Sipperley JO, Dugel PU, Sneed SR, Park DW, Cornelius J. Large-spot size transpupillary thermotherapy for the treatment of occult choroidal neovascularization associated with age-related macular degeneration. Arch Ophthalmol 2003;121:817-20.
34. Kumar A, Prakash G, Singh RP. Transpupillary thermotherapy for idiopathic subfoveal choroidal neovascularization. Acta Ophthalmol Scand 2004;82:205-8.
35. Maberley DA, Chew H, Ma P, Chang A, Hollands H, Maberley A. Comparison of photodynamic therapy and transpupillary thermotherapy for subfoveal choroidal neovascularization due to age-related macular degeneration. Can J Ophthalmol 2005;40:378-83.
36. Benner JD, Ahuja RM, Butler JW. Macular infarction after transpupillary thermotherapy for subfoveal choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 2002;134:765-8.
37. Benhamou N, Cohen SY, Erginay A, et al. Macular burn after transpupillary thermotherapy for occult choroidal neovascularization. Am J Ophthalmol 2004;137:1132-5.
38. Thompson JT. Retinal pigment epithelial tear after transpupillary thermotherapy for choroidal neovascularization. Am J Ophthalmol 2001;131:662-4.
39. Kaga T, Fonseca RA, Dantas MA, Spaide RF. Transient appearance of classic choroidal neovascularization after transpupillary thermotherapy for occult choroidal neovascularization. Retina 2001;21:172-3.
40. IRIDEX Announces Favorable TTT4CNV Clinical Trial Sub-Group Results. IRIDEX website: http://phx.corporate-ir.net/phoenix.zhtml?c=112360&p=irol- newsArticle&ID=678420&highlight=TTT4CNV. Accessed 1 Apr 2007.
41. IRIDEX Announces Confirmation of Favorable Age-Related Macular Degeneration (AMD) Results in TTT4CNV Clinical Trial Sub-Group. IRIDEX website: http://phx.corporate-ir.net/phoenix.zhtml?c=112360&p=irol- newsArticle&ID=704648&highlight=TTT4CNV. Accessed 1 Apr 2007.
42. Kvanta A, Algvere PV, Berglin L, Seregard S. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci 1996;37:1929-34.
43. Tolentino MJ, McLeod DS, Taomoto M, Otsuji T, Adamis AP, Lutty GA. Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate. Am J Ophthalmol 2002;133:373-85.
44. Adamis AP, Shima DT, Tolentino MJ, et al. Inhibition of vascular endothelial growth factor prevents retinal ischemia associated iris neovascularization in a nonhuman primate. Arch Ophthalmol 1996;114:66-71.
45. Krzystolik MG, Afshari MA, Adamis AP, et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol 2002;120:338-46.
46. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR; VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-16.
47. van Wijngaarden P, Coster DJ, Williams KA. Inhibitors of ocular neovascularization: promises and potential problems. JAMA 2005;293:1509-13.
48. Gaudreault J, Fei D, Rusit J, Suboc P, Shiu V. Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci 2005;46:726-33.
49. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-31.
50. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-44.
51. Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 2005;333:328-35.
52. Bashshur ZF, Bazarbachi A, Schakal A, Haddad ZA, El Haibi CP, Noureddin BN. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 2006;142:1-9.
53. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005;36:331-5.
54. Rich RM, Rosenfeld PJ, Puliafito CA, et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 2006;26:495-511.
55. Spaide RF, Laud K, Fine HF, et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 2006;26:383-90.
56. Fernando NH, Hurwitz HI. Targeted therapy of colorectal cancer: clinical experience with bevacizumab. Oncologist 2004;9(Suppl 1):11S-18S.
57. Fung AE, Rosenfeld PJ, Reichel E. The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 2006;90:1344-9.
58. Ziemssen F, Grisanti S, Bartz-Schmidt KU. The international intravitreal bevacizumab safety survey. Br J Ophthalmol 2006;90:1440-1.
59. Kaven C, Spraul CW, Zavazava N, Lang GK, Lang GE. Thalidomide and prednisolone inhibit growth factor-induced human retinal pigment epithelium cell proliferation in vitro. Ophthalmologica 2001;215:284-9.
60. Folkman J, Ingber DE. Angiostatic steroids. Method of discovery and mechanism of action. Ann Surg 1987;206:374-83.
61. Penfold PL, Gyory JF, Hunyor AB, Billson FA. Exudative macular degeneration and intravitreal triamcinolone. A pilot study. Aust NZ J Ophthalmol 1995;23:293-8.
62. Challa JK, Gillies MC, Penfold PL, Gyory JF, Hunyor AB, Billson FA. Exudative macular degeneration and intravitreal triamcinolone: 18 month follow up. Aust NZ J Ophthalmol 1998;26:277-81.
63. Danis RP, Ciulla TA, Pratt LM, Anliker W. Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina 2000;20:244-50.
64. Gillies MC, Simpson JM, Luo W, et al. A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: one-year results. Arch Ophthalmol 2003;121:667-73.
65. Jonas JB, Kreissig I, Hugger P, Sauder G, Panda-Jonas S, Degenring R. Intravitreal triamcinolone acetonide for exudative age related macular degeneration. Br J Ophthalmol 2003;87:462-8.
66. Jonas JB, Akkoyun I, Budde WM, Kreissig I, Degenring RF. Intravitreal reinjection of triamcinolone for exudative age-related macular degeneration. Arch Ophthalmol 2004;122:218-22.
67. Jonas JB, Degenring RF, Kreissig I, Friedemann T, Akkoyun I. Exudative age-related macular degeneration treated by intravitreal triamcinolone acetonide. A prospective comparative nonrandomized study. Eye 2005;19:163-70.
68. Spaide RF, Sorenson J, Maranan L. Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization. Ophthalmology 2003;110:1517-25.
69. Augustin AJ, Schmidt-Erfurth U. Verteporfin and intravitreal triamcinolone acetonide combination therapy for occult choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 2006;141:638-45.
70. Augustin AJ, Schmidt-Erfurth U. Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2006;113:14-22.
71. Chan WM, Lai TY, Wong AL, Tong JP, Liu DT, Lam DS. Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of subfoveal choroidal neovascularisation in age related macular degeneration: a comparative study. Br J Ophthalmol 2006;90:337-41.
72. Arias L, Garcia-Arumi J, Ramon JM, Badia M, Rubio M, Pujol O. Photodynamic therapy with intravitreal triamcinolone in predominantly classic choroidal neovascularization: one-year results of a randomized study. Ophthalmology 2006;113:2243-50.
73. Zarbin M. Should corticosteroids be considered as part of the standard care with photodynamic therapy? Arch Ophthalmol 2006;124:563-71.
74. Penn JS, Rajaratnam VS, Collier RJ, Clark AF. The effect of an angiostatic steroid on neovascularization in a rat model of retinopathy of prematurity. Invest Ophthalmol Vis Sci 2001;42:283-90.
75. Clark AF. AL-3789: a novel ophthalmic angiostatic steroid. Expert Opin Investig Drugs 1997;6:1867-77.
76. D'Amico DJ, Goldberg MF, Hudson H, et al. Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in age-related macular degeneration: twelve-month clinical outcomes. Ophthalmology 2003;110:2372-85.
77. Augustin AJ, D'Amico DJ, Mieler WF, Schneebaum C, Beasley C. Safety of posterior juxtascleral depot administration of the angiostatic cortisene anecortave acetate for treatment of subfoveal choroidal neovascularization in patients with age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2005;243:9-12.
78. D'Amico DJ, Goldberg MF, Hudson H, et al. Anecortave acetate as monotherapy for the treatment of subfoveal lesions in patients with exudative age-related macular degeneration (AMD): interim (month 6) analysis of clinical safety and efficacy. Retina 2003;23:14-23.
79. Saishin Y, Silva RL, Saishin Y, et al. Periocular injection of microspheres containing PKC412 inhibits choroidal neovascularization in a porcine model. Invest Ophthalmol Vis Sci 2003;44:4989-93.
80. Fabbro D, Ruetz S, Bodis S, et al. PKC412 - a protein kinase inhibitor with a broad therapeutic potential. Anticancer Drug Des 2000;15:17-28.
81. Cheng L, Rivero ME, Garcia CR, et al. Evaluation of intraocular pharmacokinetics and toxicity of prinomastat (AG3340) in the rabbit. J Ocul Pharmacol Ther 2001;17:295-304.
82. Ciulla TA, Criswell MH, Danis RP, Williams JI, McLane MP, Holroyd KJ. Squalamine lactate reduces choroidal neovascularization in a laser-injury model in the rat. Retina 2003;23:808-14.
83. Miller JW, Stinson WG, Folkman J. Regression of experimental iris neovascularization with systemic alpha-interferon. Ophthalmology 1993;100:9-14.
84. Pharmacological Therapy for Macular Degeneration Study Group. Interferon alfa-2a is ineffective for patients with choroidal neovascularization secondary to age-related macular degeneration. Results of a prospective randomized placebo-controlled clinical trial. Arch Ophthalmol 1997;115:865-72.
85. Hawkins BS, Bressler NM, Miskala PH, et al. Surgery for subfoveal choroidal neovascularization in age-related macular degeneration: ophthalmic findings: SST report no. 11. Ophthalmology 2004;111:1967-80.
86. Grossniklaus HE, Miskala PH, Green WR, et al. Histopathologic and ultrastructural features of surgically excised subfoveal choroidal neovascular lesions: submacular surgery trials report no. 7. Arch Ophthalmol 2005;123:914-21.
87. van Meurs JC, ter Averst E, Hofland LJ, et al. Autologous peripheral retinal pigment epithelium translocation in patients with subfoveal neovascular membranes. Br J Ophthalmol 2004;88:110-3.
88. Semkova I, Kreppel F, Welsandt G, et al. Autologous transplantation of genetically modified iris pigment epithelial cells: a promising concept for the treatment of age-related macular degeneration and other disorders of the eye. Proc Natl Acad Sci USA 2002;99:13090-5.
89. Fujii GY, Au Eong KG, Humayun MS, de Juan E Jr. Limited macular translocation: current concepts. Ophthalmol Clin North Am 2002;15:425-36.
90. Koh SS, Arroyo J. Macular translocation with 360-degree retinotomy for treatment of exudative age-related macular degeneration. Int Ophthalmol Clin 2004;44:73-81.
91. Mruthyunjaya P, Stinnett SS, Toth CA. Change in visual function after macular translocation with 360 degrees ret inectomy for neovascular age-related macular degeneration. Ophthalmology 2004;111:1715-24.
92. Aisenbrey S, Lafaut BA, Szurman P, et al. Macular translocation with 360 degrees retinotomy for exudative age-related macular degeneration. Arch Ophthalmol 2002;120:451-9.
93. Pieramici DJ, De Juan E Jr, Fujii GY, et al. Limited inferior macular translocation for the treatment of subfoveal choroidal neovascularization secondary to age-related macular degeneration. Am J Ophthalmol 2000;130:419-28.
94. Fujii GY, Pieramici DJ, Humayun MS, et al. Complications associated with limited macular translocation. Am J Ophthalmol 2000;130:751-62.
95. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 2001;119:1417-36.
96. Evans JR. Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration. Cochrane Database Syst Rev 2006;(2):CD000254.
97. Mitchell J, Bradley C. Quality of life in age-related macular degeneration: a review of the literature. Health Qual Life Outcomes 2006;4:97.
98. Virgili G, Acosta R. Reading aids for adults with low vision. Cochrane Database Syst Rev 2006;(4):CD003303.